Hijacking Low-Density Lipoprotein Receptor For Extracellular Protein Degradation And Degrader-Drug Conjugates

Invention Novelty

Value Proposition

Technology Description

UCSF researchers have developed a new bifunctional antibody for modulation of membrane
proteins, offering a dual approach of targeted degradation and potent cell killing by using low-
density lipoprotein receptor targeting chimeras with a cytotoxic payload. This new innovation
offers several compelling benefits in the biopharmaceutical and oncology sectors to enhance
efficacy in targeting and killing cancer cells, combine protein degradation with cytotoxic payload
delivery, targeting membrane-bound or secreted proteins, and reduces dose-limiting toxicities.

Application

Looking for Partners

Stage of Development

Related Materials

Data Availability